A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma

Trial Identifier: D822GC00001
Sponsor: AstraZeneca
Start Date: December 2023
Primary Completion Date: July 2028
Study Completion Date: July 2028

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
AU Heidelberg, AU, 3084
AU Kogarah, AU, NSW 2217
AU Nedlands, AU, 6009
AU Sydney, AU, 2109
BR Porto Alegre, BR, 90035-003
BR Rio de Janeiro, BR, 22061-080
BR Sao Paulo, BR, 01401-002
BR São Paulo, BR, 05403-010
CA, AB Edmonton, AB, CA, T6G 1Z2
CA, BC Vancouver, BC, CA, V5Z 4E6
CA, NS Halifax, NS, CA, B3H 2Y9
CA, ON Barrie, ON, CA, L4M 6M2
CA, ON Toronto, ON, CA, M5G 2M9
CA, QC Montreal, QC, CA, H3T 1E2
ES Madrid, ES, 28041
GB Birmingham, GB, B9 5SS
GB Gloucester, GB, GL1 3NN
GB London, GB, SW3 6JJ
GB Norwich, GB, NR4 7UY
GB Nottingham, GB, NG5 1PB
GB Plymouth, GB, PL68BQ
PL Gdynia, PL, 81-519
PL Kraków, PL, 30-727
PL Warszawa, PL, 02-781
US, NJ Hackensack, NJ, US, 07601
US, NY Stony Brook, NY, US, 11794
US, OH Cleveland, OH, US, 44195
US, PA Philadelphia, PA, US, 19104
US, TX Houston, TX, US, 77030